{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:21:32Z","timestamp":1758759692707,"version":"3.44.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40268-025-00521-w","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T12:54:50Z","timestamp":1755867290000},"page":"275-284","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bioequivalence Study of Two Formulations of Flunarizine Hydrochloride Capsules in Healthy Chinese Subjects Under Fasting and Fed Conditions"],"prefix":"10.1007","volume":"25","author":[{"given":"Yinglin","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiejing","family":"Kai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duo","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huili","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianzhong","family":"Shentu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3964-9168","authenticated-orcid":false,"given":"Guolan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1\u2013211.","key":"521_CR1","DOI":"10.1177\/0333102417738202"},{"issue":"1","key":"521_CR2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s10194-017-0765-7","volume":"18","author":"M Zebenigus","year":"2017","unstructured":"Zebenigus M, Tekle-Haimanot R, Worku DK, et al. The burden of headache disorders in Ethiopia: national estimates from a population-based door-to-door survey. J Headache Pain. 2017;18(1):58.","journal-title":"J Headache Pain"},{"issue":"1","key":"521_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s10194-021-01383-8","volume":"23","author":"G Krivoshein","year":"2022","unstructured":"Krivoshein G, Tolner EA, Maagdenberg AVD, Giniatullin RA. Migraine-relevant sex-dependent activation of mouse meningeal afferents by TRPM3 agonists. J Headache Pain. 2022;23(1):4.","journal-title":"J Headache Pain"},{"issue":"6","key":"521_CR4","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/j.1526-4610.1990.hed3006366.x","volume":"30","author":"JM Elser","year":"1990","unstructured":"Elser JM, Woody RC. Migraine headache in the infant and young child. Headache. 1990;30(6):366\u20138.","journal-title":"Headache"},{"key":"521_CR5","volume":"60","author":"E Barcia","year":"2020","unstructured":"Barcia E, Sandoval V, Fernandez-Carballido A, Negro S. Flunarizine-loaded microparticles for the prophylaxis of migraine. J Drug Deliv Sci Technol. 2020;60: 12012.","journal-title":"J Drug Deliv Sci Technol"},{"key":"521_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.2165\/00003495-198427010-00002","volume":"27","author":"B Holmes","year":"1984","unstructured":"Holmes B, Brogden RN, Heel RC, Speight TC, Avery GS. Flunarizine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs. 1984;27:6\u201344.","journal-title":"Drugs"},{"issue":"2\u20133","key":"521_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/0014-2999(91)90526-V","volume":"197","author":"C Ambrosio","year":"1991","unstructured":"Ambrosio C, Stefanini E. Interaction of flunarizine with dopamine D2 and D1 receptors. Eur J Pharmacol. 1991;197(2\u20133):221\u20133.","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"521_CR8","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/j.1526-4610.1983.hed2302070.x","volume":"23","author":"WK Amery","year":"1983","unstructured":"Amery WK. Flunarizine, a calcium channel blocker: a new prophylactic drug in migraine. Headache. 1983;23(2):70\u20134.","journal-title":"Headache"},{"issue":"1","key":"521_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/00207454.2021.1881091","volume":"133","author":"W Li","year":"2023","unstructured":"Li W, Liu R, Liu W, Li G, Chen C. The effect of topiramate versus flunarizine on the non-headache symptoms of migraine. Int J Neurosci. 2023;133(1):19\u201325.","journal-title":"Int J Neurosci"},{"issue":"12","key":"521_CR10","first-page":"1466","volume":"87","author":"A Visudtibhan","year":"2004","unstructured":"Visudtibhan A, Lusawat A, Chiemchanya S, Visudhiphan P. Flunarizine for prophylactic treatment of childhood migraine. J Med Assoc Thai. 2004;87(12):1466\u201370.","journal-title":"J Med Assoc Thai"},{"issue":"11","key":"521_CR11","volume":"16","author":"ND Vaswani","year":"2024","unstructured":"Vaswani ND, Lamba P, Arya V, Lekhwani S. Flunarizine versus propranolol in prophylaxis of pediatric migraine: an open-label randomized trial. Cureus. 2024;16(11): e74563.","journal-title":"Cureus"},{"issue":"6","key":"521_CR12","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/ene.13621","volume":"25","author":"N Karsan","year":"2018","unstructured":"Karsan N, Palethorpe D, Rattanawong W, Marin JC, Bhola R, Goadsby PJ. Flunarizine in migraine-related headache prevention: results from 200 patients treated in the UK. Eur J Neurol. 2018;25(6):811\u20137.","journal-title":"Eur J Neurol"},{"issue":"3","key":"521_CR13","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/j.1469-8749.2011.04152.x","volume":"54","author":"I Abu-Arafeh","year":"2012","unstructured":"Abu-Arafeh I. Flunarizine for the prevention of migraine: a new look at an old drug. Dev Med Child Neurol. 2012;54(3):204\u20135.","journal-title":"Dev Med Child Neurol"},{"issue":"4","key":"521_CR14","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/ane.12626","volume":"135","author":"KL Lai","year":"2017","unstructured":"Lai KL, Niddam DM, Fuh JL, et al. Flunarizine versus topiramate for chronic migraine prophylaxis: a randomized trial. Acta Neurol Scand. 2017;135(4):476\u201383.","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"521_CR15","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s10194-023-01657-3","volume":"24","author":"CI Deligianni","year":"2023","unstructured":"Deligianni CI, Sacco S, Ekizoglu E, et al. European headache federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention-part 2: flunarizine. J Headache Pain. 2023;24(1):128.","journal-title":"J Headache Pain"},{"key":"521_CR16","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1111\/j.1468-1331.2009.02748.x","volume":"16","author":"S Evers","year":"2009","unstructured":"Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine: revised report of an EFNS task force. Eur J Neurol. 2009;16:968\u201381.","journal-title":"Eur J Neurol"},{"unstructured":"AA Pharma Inc. Flunarizine hydrochloride capsules [product monograph]. 2010. https:\/\/www.aapharma.ca\/downloads\/en\/PIL\/2016\/Flunarizine-PM.pdf. Accessed 6 Aug 2025.","key":"521_CR17"},{"issue":"4","key":"521_CR18","first-page":"276","volume":"8","author":"Q Liu","year":"2010","unstructured":"Liu Q, Zhang X, Zhao H, et al. Pharmacokinetics and bioequivalence of flunarizine hydrochloride capsules in healthy volunteers. Cent South Pharm. 2010;8(4):276\u201380.","journal-title":"Cent South Pharm."},{"issue":"4","key":"521_CR19","first-page":"400","volume":"16","author":"Y Chen","year":"2011","unstructured":"Chen Y, Tan Z, Wang Y, et al. LC-MS\/MS determination of flunarizine in human plasma and application in bioequivalence evaluation. Chin J Clin Pharmacol Ther. 2011;16(4):400\u20136.","journal-title":"Chin J Clin Pharmacol Ther."},{"issue":"3","key":"521_CR20","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/cpdd.1012","volume":"11","author":"Y Xu","year":"2022","unstructured":"Xu Y, Yi Z, Li X, et al. Pharmacokinetics of flunarizine hydrochloride after single oral doses in healthy subjects: bioequivalence study and food effects. Clin Pharmacol Drug Dev. 2022;11(3):341\u20137.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"06","key":"521_CR21","first-page":"1115","volume":"25","author":"Q Wang","year":"2022","unstructured":"Wang Q, Tian Q, Xu Y, et al. Bioequivalence of flunarizine hydrochloride capsules under fasting and feeding conditions in Chinese healthy volunteers. China Pharmacist. 2022;25(06):1115\u201320.","journal-title":"China Pharmacist."},{"issue":"9","key":"521_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.4582","volume":"33","author":"A Bhadoriya","year":"2019","unstructured":"Bhadoriya A, Shah PA, Shrivastav PS, Sanyal M, Yadav MS. A high-throughput LC-MS\/MS method for determination of flunarizine in human plasma: pharmacokinetic study with different doses. Biomed Chromatogr. 2019;33(9): e4582.","journal-title":"Biomed Chromatogr"},{"unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP): guideline on the investigation of bioequivalence. 2010. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-bioequivalence-rev1_en.pdf. Accessed 6 Aug 2025.","key":"521_CR23"},{"unstructured":"National Medical Products Administration. Technical guideline for bioequivalence studies of generic drugs using pharmacokinetic parameters as endpoints. 2016. https:\/\/www.nmpa.gov.cn\/directory\/web\/nmpa\/images\/MjAxNsTqtdo2MbrFzai45ri9vP4zLmRvY3g=.docx. Accessed 6 Aug 2025.","key":"521_CR24"},{"issue":"9","key":"521_CR25","doi-asserted-by":"publisher","first-page":"5729","DOI":"10.1007\/s10072-022-06178-6","volume":"43","author":"MF Rossi","year":"2022","unstructured":"Rossi MF, Tumminello A, Marconi M, et al. Sex and gender differences in migraines: a narrative review. Neurol Sci. 2022;43(9):5729\u201334.","journal-title":"Neurol Sci"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-025-00521-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-025-00521-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-025-00521-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T20:03:11Z","timestamp":1758744191000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-025-00521-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["521"],"URL":"https:\/\/doi.org\/10.1007\/s40268-025-00521-w","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"type":"print","value":"1174-5886"},{"type":"electronic","value":"1179-6901"}],"subject":[],"published":{"date-parts":[[2025,8,22]]},"assertion":[{"value":"27 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This trial was financially funded by the company of Chiatai Qingchunbao Pharmaceutical Co., Ltd (Hangzhou, China).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Yinglin Yang, Jiejing Kai, Duo Lv, Huili Zhou, Yan Yu, Jianzhong Shentu, and Guolan Wu have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"The final study protocol was approved by the Ethics Committee of the First Affiliated Hospital, Zhejiang University School of Medicine on 15 November, 2018 (Approval No. 2018-EC-333).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Before any procedures were performed, subjects signed a written informed permission and were allowed to withdraw from the study at any moment.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author upon reasonable request. For data access, please contact the corresponding author at yilanlan_001@163.com.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable. The study used only licensed commercial software without any custom code.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"GW and JS were involved in the study\u2019s conception, design, and planning. YY, JK, YY, and HZ were all involved in the clinical trial\u2019s execution, data collection, and interpretation. DL was in charge of the research project\u2019s quality control. YY and GW were responsible for the data analysis, findings interpretation, and manuscript drafting. All authors read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}